Adding Sunharbo (asundexian), a first-in-class Factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.
News|Articles|May 1, 2002
Lercanidipine: A long-acting dihydropyridine calcium channel blocker for treatment of hypertension
Lercanidipine is currently under FDA review for the management of hypertension. In comparative clinical trials, lercanidipine has shown antihypertensive efficacy comparable to that of slow-release nifedipine, amlodipine, nitrendipine, verapamil, captopril, and atenolol. Its side effect profile is similar or superior to these agents. This Focus article reviews those trials as well as lercanidipine?s pharmacologic properties and addresses the agent?s potential role in patients with comorbid conditions.
Advertisement
Advertisement
Related to this article
In this discussion, University College London colleagues Joshua Stott, Ph.D., professor of aging and clinical psychology and research assistant Lucy Corrigan, who led the work while at the University of Liverpool, talk about their recent meta-analysis linking ADHD to a higher risk of death from all causes, including suicide, injury and natural causes.
The American Academy of Sleep Medicine’s first update since 2007 favors generic drugs, caffeine, light and naps, and advises against benzodiazepines.
People with advanced Parkinson’s disease who also have a sleep disorder cost about $50,000 a year to treat, $13,000 more than similar patients without one, according to an AbbVie-funded claims analysis.
Geisinger Health Plan President Jeremy Gaskill says the possibility that a growing number of patients won't have health insurance could put tremendous financial pressure on the plan's providers.
γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.
Upstream payment accuracy should reduce avoidable noise before it reaches those downstream functions.
The results come several months after the FDA approved Lisraya for dermatomyositis.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
As psychedelic drugs near FDA decisions, people with HIV remain absent from trials, commentary says
2
Payment integrity is necessary. But timing determines its impact
3
Quick Q&A: Christopher Stanley, M.D., MBA, on population health and healthcare affordability
4
A little-known immune cell could explain why some small cell lung cancer patients respond to immunotherapy
5